Specialty trend reached $62.25 PMPM (+11.1%), largely from utilization growth in oncology, immunology, and dermatology; ...

The therapies are incredible, says Will Shrank, M.D. They can “totally transform the lives of those who can benefit.” But ...

Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the ...

A fall 2026 close would add four Trinity hospitals in eastern Ohio to UPMC’s 40-hospital enterprise, extending reach beyond ...

After step-up dosing, treatment with bispecific antibodies does not require the use of steroids, Adams noted, so patients are ...

Financial hardship correlated strongly with nonadherence, with 37.3% of nonadherent participants unable to get by financially ...

Cross-sectional secondary analyses used SF-36 pain interference responses and medical-record diagnoses to operationalize ...

Formulary preference will shift from Stelara to interchangeable Pyzchiva and Yesintek, aiming for low-friction conversion ...

Levitt said KFF polling suggests patient frustration with prior authorization remains widespread across employer-sponsored ...

The Wall Street Journal reports that FDA Commissioner Marty Makary is being fired, signaling imminent leadership disruption ...

Will Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is leading a startup ...

Politico and The Washington Post report Makary will resign Tuesday, ending a turbulent 13-month period overseeing drug, ...